Targeting Mitochondrial Dysfunction

For our lead product, Imeglimin, a New Drug Application was submitted in Japan by Sumitomo Dainippon Pharma in July 2020. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Announces availability of its 2020 Universal Registration Document

Lyon, France, March 25, 2021 – POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes…

Read this Press Release: Poxel Announces availability of its 2020 Universal Registration Document

Poxel Reports Financial Results for Full Year 2020 and Provides Corporate Update

Imeglimin Japanese New Drug Application (J-NDA) under review following submission by Poxel’s partner, Sumitomo Dainippon Pharma, with product launch anticipated in 20211 Successful completion of PXL770 Phase 2a…

Read this Press Release: Poxel Reports Financial Results for Full Year 2020 and Provides Corporate Update

Poxel Announces Completion of Arbitration with Merck Serono

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Announces Completion of Arbitration with Merck Serono
Click here to show the previous slide Click here to show the next slide

Upcoming Events

Mitochondria-Targeted Drug Development Summit

Kempen Life Sciences Conference

Japan Diabetes Society

Jefferies Global Healthcare Conference

JMP Securities Conference

EASL ILC

Click here to show the previous slide Click here to show the next slide